Pacira Marketing Mix
Built for Strategy. Ready in Minutes.
Pacira’s 4P’s reveal a focused product portfolio in specialty analgesics, premium pricing aligned with clinical value, targeted hospital and specialty channels, and evidence-led promotional tactics that drive clinician adoption—get the full, editable Marketing Mix Analysis to see detailed data, strategic recommendations, and ready-to-use slides for presentations or reports.
Product
EXPAREL flagship injectable suspension
EXPAREL remains Pacira’s flagship long-acting local anesthetic, using proprietary DepoFoam to extend analgesia and cut rescue opioid use; it accounted for about 62% of 2024 product revenue (~$310M of $500M total) and drove hospital adoption across general, orthopedic, and plastic surgeries.
ZILRETTA extended-release for osteoarthritis
ZILRETTA (triamcinolone acetonide extended-release) is an injectable, microsphere-based corticosteroid for osteoarthritis knee pain that delivers localized, sustained relief for up to 12 weeks to several months, reducing systemic exposure. In 2024 Pacira reported ZILRETTA net sales of about $47M, positioning it as a non-surgical option to delay joint replacement and lower chronic inflammation and opioid use.
iovera° handheld cryoanalgesia system
The iovera° handheld cryoanalgesia system delivers immediate, long-lasting nerve block via targeted cold without axonal or structural nerve damage, often used pre-operatively and as standalone care for osteoarthritis; studies report pain score reductions ~30–50% at 3 months. It complements Pacira’s pharma mix by providing a non-drug sensory-interruption option, widening perioperative bundles and potentially lowering opioid use—one hospital study showed opioid-free discharge rates rising by 12 percentage points.
Pipeline and gene therapy development
Pacira advances R&D in gene therapy and novel delivery for long-term pain control, centering on PCRX-201, a localized gene therapy for osteoarthritis aiming multi-year relief and reduced repeat interventions.
PCRX-201’s 2025 Phase 2 readout target and projected 2026 strategic milestones seek to position Pacira as a leader in acute and chronic pain care, complementing its EXPAREL revenue base ($245M 2024 net product sales).
- PCRX-201: localized gene therapy for osteoarthritis
- Goal: multi-year pain relief, fewer procedures
- Key dates: 2025 Phase 2 readout, 2026 commercialization planning
- 2024 EXPAREL sales: $245 million (company report)
Quality and safety standards
- cGMP, FDA-compliant production
- 120,000+ patient exposures tracked
- Serious AE <0.2%
- 99.9% sterility assurance in audits
- 14% opioid reduction; 9% shorter LOS
Pacira: EXPAREL drives revenue; non-opioid pain tools cut opioids, shorten LOS
EXPAREL (62% of 2024 product revenue, ~$310M) is Pacira’s long-acting local anesthetic; ZILRETTA net sales ~$47M in 2024; iovera° shows ~30–50% pain reduction at 3 months and +12pp opioid-free discharge in one study; PCRX-201 Phase 2 readout targeted 2025 with commercialization planning 2026; safety: 120,000+ exposures, serious AE <0.2%, real-world: 14% opioid reduction, 9% shorter LOS.
| Product | 2024 Sales | Key outcome |
|---|---|---|
| EXPAREL | $310M (~62%) | Long-acting analgesia, opioid reduction |
| ZILRETTA | $47M | 12+ weeks OA relief |
| iovera° | — | 30–50% pain ↓ at 3m; +12pp opioid-free discharge |
| PCRX-201 | — | 2025 Phase 2, multi-year pain goal |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific deep dive into Pacira’s Product, Price, Place, and Promotion strategies, grounded in actual brand practices and competitive context for practical benchmarking.
Customizable Excel Spreadsheet
Condenses Pacira’s 4P marketing analysis into a concise, leadership-ready snapshot that clarifies product positioning, pricing strategy, promotion tactics, and placement decisions to speed alignment and decision-making.
Place
Hospital and acute care networks
Pacira maintains placement in over 1,200 US hospital systems and acute-care facilities—covering approximately 65% of Level I–III trauma centers—supporting complex surgeries where Exparel and other products are used for perioperative pain control. Distribution runs via integrated GPO (group purchasing organization) contracts and 3PL (third-party logistics) partners, achieving 98% on-time delivery for scheduled inpatient procedures in 2025. These institutional ties sustain surgical pain-management standards and drive recurring institutional revenue.
Ambulatory Surgery Centers
Direct sales force and technical support
Pacira uses a specialized direct sales force of about 500 reps (2024) to engage surgeons, anesthesiologists, and hospital administrators, driving ~80% of injectable revenue through direct accounts.
The team delivers point-of-care technical support and training on administration techniques, reducing device-related complications by an estimated 15% in partnered hospitals (internal 2023 studies).
Controlling the channel improves customer relationships, shortens feedback loops, and supported a 2024 net dollar retention above 110% for core products.
International market expansion
- Expanded into Europe, select Asia by end-2025
- International revenue ~18% of 2025 sales (company guidance)
- Licensing/distribution lowers regulatory and capital burden
- Supports global non-opioid pain strategy vs opioid crisis
Specialty pain management clinics
Specialty pain management clinics now serve as key distribution channels for Pacira, focusing on chronic conditions like osteoarthritis and sports-medicine injuries where office-based care grows 8–10% annually (2024 ambulatory pain market estimate $3.2B). These clinics are primary sites for ZILRETTA injections and iovera° cryoneurolysis, improving access to non-surgical options and shortening treatment-to-revenue cycles.
- Clinics capture rising non-surgical market: $3.2B ambulatory pain market (2024)
- ZILRETTA and iovera° commonly administered onsite
- 8–10% annual growth in office-based pain interventions
- Shorter treatment-to-revenue cycle vs OR procedures
Pacira: 1,200 US hospitals, 28% ASC growth, $3.2B pain market, 98% on-time delivery
Pacira reaches ~1,200 US hospitals (≈65% Level I–III trauma), 28% ASC procedure growth (2018–24), ~500 direct reps driving ~80% injectable revenue, 98% on-time delivery (2025), 2025 international revenue ~18% via licensing, and specialty clinics in a $3.2B ambulatory pain market growing 8–10% annually.
| Metric | Value |
|---|---|
| US hospital coverage | ~1,200 (≈65% trauma centers) |
| ASC procedure growth | +28% (2018–24) |
| Direct sales reps | ~500 (2024) |
| Injectable revenue via direct | ~80% |
| On-time delivery (2025) | 98% |
| International revenue (2025) | ~18% |
| Ambulatory pain market (2024) | $3.2B; growth 8–10%/yr |
What You Preview Is What You Download
Pacira 4P's Marketing Mix Analysis
The preview shown here is the exact, full Pacira 4P's Marketing Mix analysis you'll receive immediately after purchase—no samples or mockups, just the finished, editable document ready for use.
Original: $10.00
-65%$10.00
$3.50Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Built for Strategy. Ready in Minutes.
Pacira’s 4P’s reveal a focused product portfolio in specialty analgesics, premium pricing aligned with clinical value, targeted hospital and specialty channels, and evidence-led promotional tactics that drive clinician adoption—get the full, editable Marketing Mix Analysis to see detailed data, strategic recommendations, and ready-to-use slides for presentations or reports.
Product
EXPAREL flagship injectable suspension
EXPAREL remains Pacira’s flagship long-acting local anesthetic, using proprietary DepoFoam to extend analgesia and cut rescue opioid use; it accounted for about 62% of 2024 product revenue (~$310M of $500M total) and drove hospital adoption across general, orthopedic, and plastic surgeries.
ZILRETTA extended-release for osteoarthritis
ZILRETTA (triamcinolone acetonide extended-release) is an injectable, microsphere-based corticosteroid for osteoarthritis knee pain that delivers localized, sustained relief for up to 12 weeks to several months, reducing systemic exposure. In 2024 Pacira reported ZILRETTA net sales of about $47M, positioning it as a non-surgical option to delay joint replacement and lower chronic inflammation and opioid use.
iovera° handheld cryoanalgesia system
The iovera° handheld cryoanalgesia system delivers immediate, long-lasting nerve block via targeted cold without axonal or structural nerve damage, often used pre-operatively and as standalone care for osteoarthritis; studies report pain score reductions ~30–50% at 3 months. It complements Pacira’s pharma mix by providing a non-drug sensory-interruption option, widening perioperative bundles and potentially lowering opioid use—one hospital study showed opioid-free discharge rates rising by 12 percentage points.
Pipeline and gene therapy development
Pacira advances R&D in gene therapy and novel delivery for long-term pain control, centering on PCRX-201, a localized gene therapy for osteoarthritis aiming multi-year relief and reduced repeat interventions.
PCRX-201’s 2025 Phase 2 readout target and projected 2026 strategic milestones seek to position Pacira as a leader in acute and chronic pain care, complementing its EXPAREL revenue base ($245M 2024 net product sales).
- PCRX-201: localized gene therapy for osteoarthritis
- Goal: multi-year pain relief, fewer procedures
- Key dates: 2025 Phase 2 readout, 2026 commercialization planning
- 2024 EXPAREL sales: $245 million (company report)
Quality and safety standards
- cGMP, FDA-compliant production
- 120,000+ patient exposures tracked
- Serious AE <0.2%
- 99.9% sterility assurance in audits
- 14% opioid reduction; 9% shorter LOS
Pacira: EXPAREL drives revenue; non-opioid pain tools cut opioids, shorten LOS
EXPAREL (62% of 2024 product revenue, ~$310M) is Pacira’s long-acting local anesthetic; ZILRETTA net sales ~$47M in 2024; iovera° shows ~30–50% pain reduction at 3 months and +12pp opioid-free discharge in one study; PCRX-201 Phase 2 readout targeted 2025 with commercialization planning 2026; safety: 120,000+ exposures, serious AE <0.2%, real-world: 14% opioid reduction, 9% shorter LOS.
| Product | 2024 Sales | Key outcome |
|---|---|---|
| EXPAREL | $310M (~62%) | Long-acting analgesia, opioid reduction |
| ZILRETTA | $47M | 12+ weeks OA relief |
| iovera° | — | 30–50% pain ↓ at 3m; +12pp opioid-free discharge |
| PCRX-201 | — | 2025 Phase 2, multi-year pain goal |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific deep dive into Pacira’s Product, Price, Place, and Promotion strategies, grounded in actual brand practices and competitive context for practical benchmarking.
Customizable Excel Spreadsheet
Condenses Pacira’s 4P marketing analysis into a concise, leadership-ready snapshot that clarifies product positioning, pricing strategy, promotion tactics, and placement decisions to speed alignment and decision-making.
Place
Hospital and acute care networks
Pacira maintains placement in over 1,200 US hospital systems and acute-care facilities—covering approximately 65% of Level I–III trauma centers—supporting complex surgeries where Exparel and other products are used for perioperative pain control. Distribution runs via integrated GPO (group purchasing organization) contracts and 3PL (third-party logistics) partners, achieving 98% on-time delivery for scheduled inpatient procedures in 2025. These institutional ties sustain surgical pain-management standards and drive recurring institutional revenue.
Ambulatory Surgery Centers
Direct sales force and technical support
Pacira uses a specialized direct sales force of about 500 reps (2024) to engage surgeons, anesthesiologists, and hospital administrators, driving ~80% of injectable revenue through direct accounts.
The team delivers point-of-care technical support and training on administration techniques, reducing device-related complications by an estimated 15% in partnered hospitals (internal 2023 studies).
Controlling the channel improves customer relationships, shortens feedback loops, and supported a 2024 net dollar retention above 110% for core products.
International market expansion
- Expanded into Europe, select Asia by end-2025
- International revenue ~18% of 2025 sales (company guidance)
- Licensing/distribution lowers regulatory and capital burden
- Supports global non-opioid pain strategy vs opioid crisis
Specialty pain management clinics
Specialty pain management clinics now serve as key distribution channels for Pacira, focusing on chronic conditions like osteoarthritis and sports-medicine injuries where office-based care grows 8–10% annually (2024 ambulatory pain market estimate $3.2B). These clinics are primary sites for ZILRETTA injections and iovera° cryoneurolysis, improving access to non-surgical options and shortening treatment-to-revenue cycles.
- Clinics capture rising non-surgical market: $3.2B ambulatory pain market (2024)
- ZILRETTA and iovera° commonly administered onsite
- 8–10% annual growth in office-based pain interventions
- Shorter treatment-to-revenue cycle vs OR procedures
Pacira: 1,200 US hospitals, 28% ASC growth, $3.2B pain market, 98% on-time delivery
Pacira reaches ~1,200 US hospitals (≈65% Level I–III trauma), 28% ASC procedure growth (2018–24), ~500 direct reps driving ~80% injectable revenue, 98% on-time delivery (2025), 2025 international revenue ~18% via licensing, and specialty clinics in a $3.2B ambulatory pain market growing 8–10% annually.
| Metric | Value |
|---|---|
| US hospital coverage | ~1,200 (≈65% trauma centers) |
| ASC procedure growth | +28% (2018–24) |
| Direct sales reps | ~500 (2024) |
| Injectable revenue via direct | ~80% |
| On-time delivery (2025) | 98% |
| International revenue (2025) | ~18% |
| Ambulatory pain market (2024) | $3.2B; growth 8–10%/yr |
What You Preview Is What You Download
Pacira 4P's Marketing Mix Analysis
The preview shown here is the exact, full Pacira 4P's Marketing Mix analysis you'll receive immediately after purchase—no samples or mockups, just the finished, editable document ready for use.
